The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Why would Avacta want to take the Mologic ISO accreditation now when it will have its own by the end of March? The obvious explanation is that it wants to supply the market with tests before the end of March. Schools anyone?
Waiting for Boris. Game on!
We won’t need to wait for Boris in the House of Commons all is likely to be revealed in one of the papers tomorrow most likely the ST. Different tests for different markets both within the UK and beyond, throw in BAMS and we could well corner a fair proportion of the global market. We are indeed in a better position than last night as it looks as though we have one test through, AN, to be announced Monday and the saliva test shortly to be approved. RNS for me nailed on at some stage on Monday with the TU later in the week to clarify some of the issues raised today
The timing of the after hours publication of the article and the status of the author both indicate a deliberate leak by Whitehall in the knowledge that it would be picked up by the wider media. The only surprise was that there was no leak prior to publication. Leaking key information in this way is the modus operandi of this Government. A 7am RNS inevitable unless the SP is suspended prior to Bojo’s statement. The issue for us is how many manufacturers globally have been lined up as we should not become obsessed by the UK market. What part will Medusa play? Congratulations to all LTH and particularly Al and his team who have received unwarranted stick for circumstances not of their making.
The point about trust is a very good one as this has been undermined by the quality of the first generation tests. Bojo needs to address this issue and if he can wrap it around the UK leading the world in diagnostic testing as well as vaccinations he will do.Great news for cancer sufferers today and reinforces the view to people observing AVCT for the first time we are very much not a one trick pony. The other point is the UK is a mere 1% of the global market and we also have BAMS
Listened to a number of media outlets today and without exception it has included people questioning the validity of the present LFT and their concerns about the impact of false negatives. Clearly few if any people are joining the dots up from our initial test results announced yesterday. In order to stop further erosion of The credibility of the the LFD before roll out there has to be a Government backed PR campaign explaining the improvements to accuracy of the new second generation tests. Step forward AVCT
Who knows may drop in to BBI solutions??
Whilst the SP moves inevitably towards and beyond £2 a quick thank you to Myles, Ophidian, BBN and others who no longer comment on here but whose research in the past have helped people like myself to build a substantial holding in this company
Fantastic initial results. Congratulations to all patient LTH and to all those who always had confidence in the work of Alastair and his team. The affimer is derisked!
The clear takeaway message from tonight’s briefing is that the route back into mass gatherings will not be vaccine passports but the taking of the rapid lateral flow tests. Great news for Avct shareholders and all eyes on that trading update
We have been given a route to market for our tests. With the Mologic collaboration first to market is scheduled for the end of next month and for the sovereign test which we are highly likely to be involved in the 2 million per day target has been set towards the end of April. Fingers crossed those timelines are met this time
So joining a few dots one possible scenario and totally speculative of course is that Avct is developing 2 LFD tests in addition to BAMS and Elisa.
One test is in collaboration with Mologic and was detailed on Monday under the Avct trademark which is primarily aimed at the global market and which is presently been evaluated at an unnamed European hospital. The test is a forerunner to an improved hybrid test which it is hoped would be a world best and would be adapted to include other diseases as well as Covid. The original test should be hitting the market late March with other overseas manufacturers supplementing capacity as the year progresses
The second test may or will form a key part of Operation Moonshot and is subject to NDA’s which involves collaboration with all other UK relevant manufacturers and will primarily concentrate on the UK market. It will not be marketed under the Avct name but will have the affimer as its core constituent and the aim would be producing 2 million tests per day by the end of April.
So potentially one test by the end of March and the other by the end of April with BAMS whenever. Not long to wait.
You can sense the frustration in Al’s voice re the delays with the clinical trials and especially the alleged inaccuracies of the LFD compared to the PCR test which he very clearly explains. Stellar performance in the labs with all to be revealed in the trading update towards the end of the month. Those people ****ging Alastair off should be ashamed of themselves and hopefully will be too stupid to take advantage of the window that now exists between now and that trading update
No mention of BBI or Abingdon so a further update to come re our involvement in the sovereign test ?
Apparently you can now trade online with Barclays for Acquis stocks with AJ Bell to follow. Dual listing to further improve liquidity still the objective. Noticeable improvement on PR particularly on their Twitter feed which they are now prioritising. Looking forward to more positive results from Mt Cassidy
Someone mentioned over the weekend that Dido was in front of one of the Select Committees tomorrow for a grilling. She is bound to be asked about testing and given a hard time over track and trace again. Wouldn’t be at all surprised if she mentioned the sovereign test particularly in the light of the Huff post last night. Definitely worth keeping an eye on
I think I am right in saying this is very good news in that the Apex segment will increase the liquidity of TTAU thereby reducing the spread. Still telephone trading though?
Some maybe disappointed holders but others are non holders whose motives could be described in a way that would get me banned from this Board. For longer term holders this is a very positive RNS and is a further vindication of the affimer technology. No interview with Al today likely signposts a further update tomorrow or Monday
It has been clear since at least last April that uncharacteristically for this Government it has been putting in place a structure that is intending to deal not only with this epidemic but future ones. At its heart is a diagnostic programme that is UK based, collaborative, and for ease of use involves the lateral flow test, a fact confirmed by Boris last night. To put such a fool proof structure in place takes time which is a commodity the typical Aim punter doesn’t have, a fact which Al mistakenly encouraged with his over optimistic timelines. If you think the affimer is at the heart of this programme then you will hold this share for the short, medium and long term benefits this will provide. If you don’t sell up and find another rainbow to chase
Priti on a news conference at 5. Guaranteed to get the story wrong so hope nobody asks her!